On this episode we speak with Greg Kunst the CEO of Aurion Biotech, a clinical stage biotech company developing a transformational platform of advanced therapies to cure blindness. Their first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

It was recently announced that they have received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for their novel cell therapy, Vyznova™, for the treatment of bullous keratopathy of the cornea.

Greg Kunst joins Aurion Biotech with deep and varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs.

Before Aurion Biotech, Greg spent 6 years at Glaukos Corporation (NYSE: GKOS) in numerous roles of increasing responsibility, most recently as vice president of global marketing, where he led the global marketing, market access, reimbursement, health economics and outcomes research, government affairs, and business development teams. Before Glaukos, Greg worked at Alcon, a Novartis company, as global franchise director over the Alcon glaucoma surgery and retina pharmaceutical businesses. Before joining Alcon, Greg worked at Kinetic Concepts, Inc. (Acelity Inc.) as the global head of market access. Greg is a member of the steering committee for the Gavin Herbert Eye Institute at the University of California, Irvine. Greg received an MBA from Vanderbilt University and a BS in Economics from Brigham Young University.